Two biotech firms are trying to cash in on investor excitement around obesity drugs and disease-detecting technology. One company wants $533 million to develop weight-loss treatments, while another seeks $159 million to expand its diagnostic tools. Both plan to sell shares to the public soon, hoping
New medications like tirzepatide and semaglutide are making waves in the fight against obesity. These drugs do more than just help people lose weight; they also reduce the chances of developing heart disease and diabetes. But there's a significant downside: they are expensive. This has sparked a hea
Elon Musk, a tech billionaire advising the incoming president, thinks the solution to America's obesity crisis lies in making new weight loss drugs cheap. Meanwhile, Robert F. Kennedy Jr. , the president-elect's pick for health secretary, believes lifestyle changes are key. Both views highlight the
